COLL - Collegium Pharmaceutical Inc Stock Price, Fair Value and News

35.48USD-0.46 (-1.28%)Market Closed

Market Summary

USD35.48-0.46

Market Closed

-1.28%

COLL Stock Price

View Fullscreen

COLL RSI Chart

COLL Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

23.85

Price/Sales (Trailing)

2.03

EV/EBITDA

5.6

Price/Free Cashflow

4.19

COLL Price/Sales (Trailing)

COLL Profitability

EBT Margin

13.36%

Return on Equity

24.64%

Return on Assets

4.21%

Free Cashflow Yield

23.88%

COLL Fundamentals

COLL Revenue

Revenue (TTM)

566.8M

Rev. Growth (Yr)

15.53%

Rev. Growth (Qtr)

9.54%

COLL Earnings

Earnings (TTM)

48.2M

Earnings Growth (Yr)

543.67%

Earnings Growth (Qtr)

54.79%

Breaking Down COLL Revenue

Last 7 days

1.5%

Last 30 days

-9.5%

Last 90 days

8.5%

Trailing 12 Months

53.6%

How does COLL drawdown profile look like?

COLL Financial Health

Current Ratio

1.17

COLL Investor Care

Buy Backs (1Y)

6.18%

Diluted EPS (TTM)

1.18

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	524.9M	536.9M	546.6M	566.8M
2022	272.9M	313.5M	361.7M	463.9M
2021	321.2M	326.1M	325.8M	276.9M
2020	298.7M	301.7M	307.9M	310.0M
2019	291.2M	293.2M	295.9M	296.7M
2018	90.1M	159.6M	217.8M	280.4M
2017	7.5M	13.2M	19.0M	28.5M
2016	6.8M	5.1M	3.4M	1.7M
2015	0	0	10.2M	8.5M
2013	0	0	0	12.0M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Collegium Pharmaceutical Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 29, 2024	smith thomas b	sold	-36,580	36.764	-995	evp and chief medical officer
Feb 26, 2024	dreyer scott	sold	-364,270	36.427	-10,000	evp & chief commercial officer
Feb 12, 2024	tupper colleen	acquired	-	-	71,456	evp & chief financial officer
Feb 12, 2024	ciaffoni joseph	acquired	-	-	298,734	president and ceo
Feb 12, 2024	dreyer scott	acquired	-	-	67,286	evp & chief commercial officer
Feb 12, 2024	smith thomas b	sold (taxes)	-107,806	33.7	-3,199	evp and chief medical officer
Feb 12, 2024	dreyer scott	sold (taxes)	-1,000,550	33.7	-29,690	evp & chief commercial officer
Feb 12, 2024	smith thomas b	acquired	-	-	35,423	evp and chief medical officer
Feb 12, 2024	kuhlmann shirley r.	sold (taxes)	-1,070,180	33.7	-31,756	evp and general counsel
Feb 12, 2024	tupper colleen	sold (taxes)	-887,018	33.7	-26,321	evp & chief financial officer

Which funds bought or sold COLL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	Values First Advisors, Inc.	reduced	-52.94	-423,730	618,645	0.36%
Apr 23, 2024	WEDGE CAPITAL MANAGEMENT L L P/NC	added	52.81	805,275	1,673,760	0.03%
Apr 23, 2024	Louisiana State Employees Retirement System	reduced	-0.61	127,170	628,884	0.01%
Apr 23, 2024	AMALGAMATED BANK	reduced	-27.3	-36,000	391,000	-%
Apr 23, 2024	NATIONS FINANCIAL GROUP INC, /IA/ /ADV	new	-	385,716	385,716	0.03%
Apr 23, 2024	FIFTH THIRD BANCORP	added	10.42	580	2,057	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	new	-	921,859	921,859	-%
Apr 22, 2024	Rosenberg Matthew Hamilton	sold off	-100	-62.00	-	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	148,883	543,606	-%
Apr 19, 2024	Maryland State Retirement & Pension System	unchanged	-	53,274	418,079	0.01%

Are Funds Buying or Selling COLL?

Are funds buying COLL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own COLL

No. of Funds

Unveiling Collegium Pharmaceutical Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	eventide asset management, llc	8.07%	2,630,478	SC 13G/A
Feb 13, 2024	vanguard group inc	7.09%	2,312,786	SC 13G/A
Feb 12, 2024	rubric capital management lp	8.46%	2,758,253	SC 13G/A
Jan 19, 2024	blackrock inc.	17.7%	5,786,527	SC 13G/A
Feb 10, 2023	rubric capital management lp	9.93%	3,333,628	SC 13G/A
Feb 09, 2023	janus henderson group plc	4.4%	1,481,170	SC 13G/A
Feb 09, 2023	vanguard group inc	6.58%	2,208,111	SC 13G/A
Jan 30, 2023	blackrock inc.	17.1%	5,731,305	SC 13G/A
Sep 09, 2022	janus henderson group plc	5.8%	1,987,495	SC 13G/A
Feb 15, 2022	perceptive advisors llc	0%	0	SC 13G/A

Recent SEC filings of Collegium Pharmaceutical Inc

View All Filings

Date Filed	Form Type	Document
Apr 11, 2024	8-K	Current Report
Apr 05, 2024	ARS	ARS
Apr 05, 2024	DEF 14A	DEF 14A
Apr 05, 2024	DEFA14A	DEFA14A
Mar 04, 2024	4	Insider Trading
Feb 29, 2024	144	Notice of Insider Sale Intent
Feb 28, 2024	4	Insider Trading
Feb 26, 2024	144	Notice of Insider Sale Intent
Feb 22, 2024	10-K	Annual Report
Feb 22, 2024	8-K	Current Report

Peers (Alternatives to Collegium Pharmaceutical Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	357.8B	85.2B	-3.67%	-8.64%	10.18	4.2	6.46%	95.94%
MRK	321.7B	60.1B	2.46%	9.45%	881.36	5.35	1.40%	-97.49%
PFE	148.3B	46.5B	-3.80%	-34.05%	-106.79	3.19	42.59%	-114.62%
AMGN	146.3B	28.2B	-0.95%	11.90%	21.78	5.19	7.09%	2.52%
GILD	83.6B	27.1B	-7.68%	-22.69%	14.75	3.08	-0.60%	23.36%
TEVA	14.6B	15.8B	-6.26%	55.93%	-25.3	0.92	6.17%	76.47%
MID-CAP
PRGO	4.1B	4.7B	-2.65%	-15.52%	-325.34	0.89	4.58%	90.97%
ALKS	4.1B	1.7B	-11.07%	-16.83%	11.39	2.44	49.61%	324.78%
BHC	3.1B	8.8B	-10.77%	12.83%	-5.27	0.36	7.79%	-163.11%
AMPH	2.0B	644.4M	-6.43%	-0.05%	14.31	3.05	29.14%	50.51%
SMALL-CAP
TLRY	1.4B	743.2M	-20.35%	-21.70%	-4.05	1.92	24.65%	80.36%
TXMD	22.3M	1.3M	-17.90%	-49.19%	-2.17	17.09	-98.14%	-109.18%
ACRX	16.3M	-	-14.29%	38.83%	-0.89	0.22	2882.68%	-138.52%
AGRX	2.5M	19.6M	-32.73%	-94.43%	-0.18	0.13	80.00%	43.08%
ACOR	645.9K	117.6M	-96.48%	-95.45%	0	0.01	-0.79%	-283.60%

Collegium Pharmaceutical Inc News

Latest updates

Collegium Pharmaceutical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	9.5%	150	137	136	145	130	127	124	84.00	27.00	79.00	83.00	88.00	76.00	79.00	78.00	77.00	74.00	73.00	75.00	75.00	73.00
Gross Profit	17.8%	95.00	80.00	74.00	77.00	50.00	59.00	52.00	48.00	-1.33	46.00	50.00	56.00	44.00	48.00	48.00	39.00	25.00	26.00	26.00	25.00	-
Costs and Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	77.00	79.00	80.00	85.00	62.00
Operating Expenses	-6.7%	33.00	35.00	38.00	53.00	38.00	38.00	41.00	59.00	33.00	32.00	34.00	34.00	29.00	29.00	32.00	34.00	27.00	33.00	31.00	35.00	55.00
S&GA Expenses	-6.7%	33.00	35.00	38.00	53.00	38.00	38.00	41.00	55.00	27.00	31.00	30.00	31.00	27.00	26.00	29.00	31.00	25.00	30.00	29.00	32.00	30.00
R&D Expenses	-	-	-	-	-	-	-	-	4.00	2.00	1.00	3.00	3.00	2.00	2.00	2.00	3.00	2.00	2.00	2.00	3.00	2.00
EBITDA Margin	43.5%	0.29*	0.20*	0.15*	0.10*	0.08*	-0.03*	-0.05*	-0.04*	0.07*	0.21*	0.23*	0.23*	-	-	-	-	-	-	-	-	-
Interest Expenses	-7.2%	19.00	21.00	22.00	21.00	21.00	19.00	18.00	6.00	5.00	5.00	5.00	6.00	8.00	8.00	8.00	5.00	0.00	0.00	0.00	0.00	2.00
Income Taxes	81.2%	15.00	8.00	5.00	-0.13	-0.59	1.00	-1.45	-2.77	-13.84	1.00	-61.85	-0.19	0.00	0.00	0.00	0.00	-	-	-	-	-
Earnings Before Taxes	62.3%	47.00	29.00	18.00	-17.56	-7.79	1.00	-6.65	-15.84	-38.88	9.00	11.00	15.00	7.00	12.00	8.00	0.00	-2.20	-6.11	-4.71	-	-
EBT Margin	244.0%	0.13*	0.04*	-0.01*	-0.06*	-0.06*	-0.17*	-0.17*	-0.13*	-0.01*	0.13*	0.14*	0.13*	-	-	-	-	-	-	-	-	-
Net Income	54.8%	32.00	21.00	13.00	-17.43	-7.20	0.00	-5.19	-13.07	-25.03	8.00	73.00	16.00	7.00	11.00	8.00	0.00	-2.20	-6.11	-4.71	-9.70	9.00
Net Income Margin	415.2%	0.08*	0.02*	-0.02*	-0.06*	-0.05*	-0.12*	-0.11*	0.16*	0.26*	0.32*	0.33*	0.13*	-	-	-	-	-	-	-	-	-
Free Cashflow	-1.1%	73.00	74.00	100	27.00	65.00	43.00	40.00	-25.42	36.00	17.00	29.00	20.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-2.9%	1,143	1,178	1,214	1,214	1,174	1,201	1,246	1,246	692	742	714	646	644	644	647	635	306	304	302	294	291
Current Assets	0.1%	538	537	537	498	420	405	410	364	316	363	319	296	278	262	251	224	256	250	245	234	238
Cash Equivalents	-7.6%	239	259	284	269	174	134	123	107	186	193	203	183	177	165	146	116	170	154	149	135	147
Inventory	-5.3%	32.00	34.00	26.00	33.00	47.00	65.00	78.00	80.00	17.00	17.00	20.00	15.00	16.00	17.00	19.00	16.00	10.00	9.00	10.00	9.00	8.00
Net PPE	-4.0%	16.00	17.00	18.00	19.00	20.00	20.00	20.00	20.00	19.00	20.00	20.00	20.00	19.00	18.00	15.00	13.00	12.00	12.00	10.00	10.00	9.00
Goodwill	0%	134	134	134	134	134	130	130	134	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	-5.1%	948	999	1,013	1,035	979	1,004	1,048	1,050	489	491	461	476	458	471	491	494	219	220	216	208	200
Current Liabilities	-1.4%	458	465	435	413	434	414	415	374	280	269	227	230	239	242	252	244	202	201	196	189	189
Shareholder's Equity	9.3%	195	179	201	180	195	197	198	196	203	251	253	170	186	173	156	141	87.00	84.00	86.00	86.00	92.00
Retained Earnings	12.0%	-233	-265	-285	-298	-281	-274	-274	-269	-256	-231	-239	-312	-333	-340	-351	-359	-359	-357	-351	-346	-337
Additional Paid-In Capital	3.7%	566	546	548	540	538	526	520	513	502	500	492	482	519	513	507	500	447	442	437	433	429
Shares Outstanding	-5.6%	32.00	34.00	35.00	34.00	34.00	34.00	34.00	34.00	35.00	35.00	35.00	35.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	742	-	-	-	600	-	-	-	831	-	-	-	599	-	-	-	416	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-0.9%	73,338	74,018	99,722	27,671	66,325	42,769	40,451	-25,315	36,198	17,254	29,535	20,570	22,577	34,180	43,854	-6,669	15,656	6,069	14,627	-8,569	42,288
Share Based Compensation	-0.4%	7,002	7,027	7,072	6,035	5,670	5,377	5,692	6,135	4,912	5,948	6,516	6,879	6,210	5,165	5,584	4,951	3,966	4,137	4,162	4,263	3,598
Cashflow From Investing	-556.6%	-25,097	-3,822	-41,717	-176	-940	-113	-461	-572,177	-515	-276	-725	-428	-1,481	-2,403	-2,241	-367,647	-889	-1,351	-875	-3,323	-1,773
Cashflow From Financing	28.9%	-67,826	-95,413	-45,236	68,297	-25,823	-31,252	-23,966	517,764	-42,498	-26,508	-8,829	-11,468	-12,403	-12,032	-12,211	323,120	1,414	407	51.00	169	-33,672
Buy Backs	-	25,000	-	-	-	7,641	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

COLL Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues
Product revenues, net	$ 566,767	$ 463,933	$ 276,868
Revenue from Contract with Customer, Product and Service [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Cost of product revenues
Cost of product revenues (excluding intangible asset amortization)	$ 94,838	$ 118,190	$ 59,070
Cost, Product and Service [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Intangible asset amortization and impairment	$ 145,760	$ 136,255	$ 67,181
Total cost of products revenues	240,598	254,445	126,251
Gross profit	326,169	209,488	150,617
Operating expenses
Research and development	0	3,983	9,451
Selling, general and administrative	159,208	172,186	118,960
Restructuring			4,578
Total operating expenses	159,208	176,169	132,989
Income from operations	166,961	33,319	17,628
Interest expense	(83,339)	(63,213)	(21,014)
Interest income	15,615	1,047	12
Loss on extinguishment of debt	(23,504)
Income (loss) before income taxes	75,733	(28,847)	(3,374)
Provision for (benefit from) income taxes	27,578	(3,845)	(74,891)
Net income (loss)	$ 48,155	$ (25,002)	$ 71,517
Earnings (loss) per share - basic (in dollars per share)	$ 1.43	$ (0.74)	$ 2.05
Weighted-average shares - basic (in shares)	33,741,213	33,829,495	34,936,817
Earnings (loss) per share - diluted (in dollars per share)	$ 1.29	$ (0.74)	$ 1.86
Weighted-average shares outstanding - diluted (in shares)	41,788,125	33,829,495	41,045,805

COLL Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 238,947	$ 173,688
Marketable securities	71,601
Accounts receivable, net	179,525	183,119
Inventory	32,332	46,501
Prepaid expenses and other current assets	15,195	16,681
Total current assets	537,600	419,989
Property and equipment, net	15,983	19,521
Operating lease assets	6,029	6,861
Intangible assets, net	421,708	567,468
Restricted cash	1,047	2,547
Deferred tax assets	26,259	23,950
Other noncurrent assets	825	100
Goodwill	133,857	133,695
Total assets	1,143,308	1,174,131
Current liabilities
Accounts payable	8,692	3,494
Accrued liabilities	37,571	36,129
Accrued rebates, returns and discounts	227,331	230,491
Current portion of term notes payable	183,333	162,500
Current portion of operating lease liabilities	988	1,112
Total current liabilities	457,915	433,726
Term notes payable, net of current portion	221,713	397,578
Convertible senior notes	262,125	140,873
Operating lease liabilities, net of current portion	6,124	7,112
Total liabilities	947,877	979,289
Commitments and contingencies (refer to Note 13)
Shareholders' equity:
Preferred stock, $0.001 par value; authorized shares - 5,000,000
Common stock, $0.001 par value; authorized shares - 100,000,000; 38,192,441 issued and 31,868,549 outstanding shares as of December 31, 2023 and 37,084,759 issued and 33,848,936 outstanding shares as of December 31, 2022	38	37
Additional paid-in capital	565,949	538,073
Treasury stock, at cost; 6,323,892 shares as of December 31, 2023 and 3,235,823 shares as of December 31, 2022	(137,381)	(61,924)
Accumulated other comprehensive income	14
Accumulated deficit	(233,189)	(281,344)
Total shareholders' equity	195,431	194,842
Total liabilities and shareholders' equity	$ 1,143,308	$ 1,174,131

About Collegium Pharmaceutical Inc

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

CEO	Mr. Joseph J. Ciaffoni
WEBSITE	collegiumpharma.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	207

Collegium Pharmaceutical Inc Frequently Asked Questions

What is the ticker symbol for Collegium Pharmaceutical Inc? What does COLL stand for in stocks?

COLL is the stock ticker symbol of Collegium Pharmaceutical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Collegium Pharmaceutical Inc (COLL)?

As of Tue Apr 23 2024, market cap of Collegium Pharmaceutical Inc is 1.15 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of COLL stock?

You can check COLL's fair value in chart for subscribers.

What is the fair value of COLL stock?

You can check COLL's fair value in chart for subscribers. The fair value of Collegium Pharmaceutical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Collegium Pharmaceutical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for COLL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Collegium Pharmaceutical Inc a good stock to buy?

The fair value guage provides a quick view whether COLL is over valued or under valued. Whether Collegium Pharmaceutical Inc is cheap or expensive depends on the assumptions which impact Collegium Pharmaceutical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for COLL.

What is Collegium Pharmaceutical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, COLL's PE ratio (Price to Earnings) is 23.85 and Price to Sales (PS) ratio is 2.03. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. COLL PE ratio will change depending on the future growth rate expectations of investors.